Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Serine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL3075852 | 1.00 | PTGS1 (0.67) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL16058500 | 1.00 | PTGS1 (0.67) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL15417923 | 0.93 | PTGS1 (0.57) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL1162414 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GSRGRM8 | |
| Cysteine SCHEMBL1268415 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL1162408 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GSRGRM8 | |
| Cysteine SCHEMBL3320713 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL17113864 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GSRGRM8 | |
| Serine SCHEMBL17113867 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GSRGRM8 | |
| Cysteine SCHEMBL3320717 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571897-B1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | BETTA PHARMACEUTICALS CO LTD (CN) | 2014-11-05 | — | — | EP | claimed |
| US-20130203672-A1 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use | BETTA PHARMACEUTICALS CO., LTD (CN) | 2013-08-08 | — | — | US | claimed |
| EP-2571897-A1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | Zhejiang Beta Pharma Inc. (CN) | 2013-03-27 | — | — | EP | claimed |
| WO-2011143788-A1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | ZHEJIANG BETA PHARMA INC. (CN) | 2011-11-24 | — | — | WO | claimed |
| WO-2024086683-A2 | FLAGELLIN EPITOPE PEPTIDES AND USES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-117898989-A | Composition for repairing skin barrier and application thereof | 上海家化联合股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117898990-A | Composition containing collagen and sweet wormwood herb extract and application thereof | 上海家化联合股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20220373561-A1 | TRANSFORMATIONAL IMMUNE DIAGNOSTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-24 | — | — | US | disclosed |
| US-20220010301-A1 | METHODS OF SELECTING FUNCTIONAL INTERFACE MIMICS, AND COMPOSITIONS THEREOF | Cowper Sciences Inc. | 2022-01-13 | — | — | US | disclosed |
| CN-113677691-A | Method for selecting functional interface simulant and composition thereof | 库博科学公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021158533-A1 | TRANSFORMATIONAL IMMUNE DIAGNOSTICS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210223257-A1 | METHOD AND SYSTEM FOR DETERMINING MICROSATELLITE INSTABILITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-20100248977-A1 | Immobilizing an Entity in a Desired Orientation on a Support Material | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2205974-A2 | IMMOBILIZING AN ENTITY IN A DESIRED ORIENTATION ON A SUPPORT MATERIAL | Arizona Board Of Regents, A Body Corporate Acting For And On Behalf Of Northern Arizona University (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010028214-A2 | SCREENING METHOD TO IDENTIFY MOLECULES HAVING THE ABILITY TO MODULATE THE ACTIVITY OF A CATALYST | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009140039-A2 | SYNTHETIC ANTIBODIES | THE ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-2076614-A2 | SYNTHETIC ANTIBODIES | The Arizona Board of Regents, A Body Corporate Of the State of Arizona acting for and on behalf Of Arizona State University (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009082417-A2 | IMMOBILIZING AN ENTITY IN A DESIRED ORIENTATION ON A SUPPORT MATERIAL | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008048970-A2 | SYNTHETIC ANTIBODIES | THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20070292379-A1 | HAIR TREATING AGENT COMPRISING CORNEOCYTE PROTEINS OR CORNEOCYTE POLYPEPTIDES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203672-A1 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use | IAPP, GLP1R, GIPR | PTGS1 3042/4885SLC7A11 1980/4885SLC1A1 2747/4885 |
| US-20070292379-A1 | HAIR TREATING AGENT COMPRISING CORNEOCYTE PROTEINS OR CORNEOCYTE POLYPEPTIDES | KRT18, S100A4, S100P | PTGS1 3041/4885SLC7A11 2307/4885SLC1A1 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.